top of page


  • Rodriguez-Bravo V*, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J*. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell. 2018 Aug 23;174(5):1200-1215.e20. doi: 10.1016/j.cell.2018.07.015. Epub 2018 Aug 9.

  • Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J. The role of GATA2 in lethal prostate cancer aggressiveness. Nat Rev Urol 2017 Jan; 14. Link to article.

  • Grau JJ, Mesía R, de la Iglesia-Vicente M, Williams ES, Taberna M, Caballero M, Larque AB, de la Oliva J, Cordón-Cardo C, Domingo-Domenech J. Enrichment of Cells with Cancer Stem Cell-Like Markers in Relapses of Chemoresistant Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. Oncology. 2016;90(5):267-72. doi: 10.1159/000445118. Epub 2016 Apr 15. Link to article.

  • Williams E, Rodriguez-Bravo V, Chippada-Venkata U, de la Iglesia J, Gong Y, Galsky M, Oh W, Cordon-Cardo C,Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. J Vis Exp 2015 Oct; 20. Link to article.

  • Vidal S, Rodriguez-Bravo V, Quinn A, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak D, Dudley J, Rabadan R, Silva J, Hoshida Y, Lowe S, Cordon-Cardo C, Domingo-Domenech J. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 2015 Feb; 27. Link to article

  • Vidal S, Quinn A, de la Iglesia J, Bonal D, Rodriguez-Bravo V, Firpo-Betancourt A, Cordon-Cardo C, Domingo-Domenech J. Isolation of cancer stem cells from human prostate cancer samples. J Vis Exp 2014 Mar; 14. Link to article.

  • Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2013 Oct. Link to article.

  • Galsky MD, Domingo-Domenech J. Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches. Clinical advances in hematology & oncology : H&O 2013 Feb; 11(2). Link to article.

  • Jia AY, Castillo-Martin M, Domingo-Domenech J, Bonal DM, Sánchez-Carbayo M, Silva JM, Cordon-Cardo C. A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. The American journal of pathology 2013 Apr; 182(4). Link to article.

  • Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer cell 2012 Sep; 22(3). Link to article.

  • Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM, Cordon-Cardo C. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. The Journal of urology 2011 Nov; 186(5). Link to article.

  • Domingo-Domènech J, Pippa R, Tápia M, Gascón P, Bachs O, Bosch M. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast cancer research and treatment 2008 Nov; 112(1). Link to article.

  • Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony J, Gascon P, Mellado B. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008 Feb; 19(2). Link to article.

  • Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Sep; 12(18). Link to article.

bottom of page